 | | Vol. 14.05 – 07 February, 2023 |
| |
|
|
| Researchers described a novel enhancer element that was important for regulating the expression of Prox1 in lymphatic endothelial cells.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To address the role for the pathogenesis of the disease, investigators expressed the NFIA-ETO2 fusion in murine erythroblasts. They observed that NFIA-ETO2 significantly increased proliferation and impaired erythroid differentiation of murine erythroleuemia cells and of primary fetal liver-derived erythroblasts.
[Blood] |
|
|
|
| Scientists identified first-in-class pleckstrin-2 (Plek2) inhibitors through an in silico high-throughput screening and cell-based assays followed by the synthesis of analogs. The Plek2-specific small molecule inhibitors showed potent inhibitory effects on cell proliferation.
[Journal Of Clinical Investigation] |
|
|
|
| Researchers found that myeloid-like B cells, which express myeloid markers, emerged in the bone marrow after the induction of emergency myelopoiesis.
[Journal Of Experimental Medicine] |
|
|
|
| Scientists studied the impact of dasatinib in chronic myeloid leukemia patients and compared with patients taking other tyrosine kinase inhibitors and healthy controls.
[Haematologica] |
|
|
|
| Investigators generated zebrafish models of isocitrate dehydrogenase 2 (IDH2)R172K and IDH2R140Q AML and reported their pathologic, functional, and transcriptomic features and therapeutic responses to target therapies.
[Oncogene] |
|
|
|
| The authors studied mice harboring a germline hypomorphic mutation of one Runx1 allele with a loss-of-function mutation in the other Runx1 allele, which displayed many hematologic characteristics found in human RUNX1 familial platelet disorder (RUNX1-FPD) patients.
[Hemasphere] |
| |
|
|
| Investigators explored baseline characteristics and predictors of erythropoiesis-stimulating agents (ESA) hyporesponsiveness in a global randomized cardiovascular outcomes study comparing an investigational hypoxia-inducible factor prolyl hydroxylase inhibitor, daprodustat, with conventional (ESA) treatment.
[American Journal of Nephrology] |
|
|
|
| Study subjects received either 8000 IU of cholecalciferol daily or a placebo for 12 weeks. Researchers evaluated the change in markers of hepcidin expression, erythropoiesis, and iron status from baseline to week 12 and compared the change between the groups.
[Bmc Nephrology] |
|
|
|
|
| The authors discuss the first generation of myeloid modulators and highlight recent developments in modeling context-specific roles for different myeloid cell subtypes, which can ultimately inform how to drive more successful clinical trials.
[Nature Reviews Cancer] |
|
|
|
| Investigators discuss the utility of molecular markers in AML in prognostication and treatment decision-making.
[Haematologica] |
|
|
|
|
| Aptose Biosciences Inc. announced the 120 mg monotherapy dosing of patients in the APTIVATE Phase I/II clinical trial of tuspetinib, an oral, mutation-agnostic tyrosine kinase inhibitor being developed for the treatment of patients with relapsed or refractory AML.
[Aptose Bioscience, Inc.] |
|
|
|
| | February 19 – 22, 2023
Banff, Alberta, Canada |
|
|
|
|
|
| | Hebrew University of Jerusalem – Jerusalem, Israel |
|
|
|
| | The University of Queensland – St. Lucia, Australia |
|
|
|
| | Dresden University of Technology – Dresden, Germany |
|
|
|
| | Albert Einstein College of Medicine – New York, New York, United States |
|
|
|
| | Lund University – Lund, Sweden |
| |
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
